You have read all your free articles, to continue reading subscribe to read the rest of this content.
The Swedish pharmaceutical development company Adenovir Pharma has started a phase II clinical study for the treatment of an infectious eye disease. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjunctivitis (EKC). There are currently no effective antiviral tAlready a subscriber Login You have read all…
Cantargia has reported new data providing further insights to the mechanisms underlying the antitumor activity of the IL1RAP-binding antibody nadunolimab (CAN04). In a model of the pancreatic cancer (PDAC) microenvironment, nadunolimab potently reduced levels of various tumor-promoting molecules,Already a subscriber Login You have read all your free articles, to continue…
The two companies have completed the phase III clinical trial (ARAMIS) of darolutamide, the novel oral androgen receptor antagonist for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). The primary endpoint of the trial was met: Darolutamide significantlAlready a subscriber Login You have read all your free articles,…
Cantargia has presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 (nidanilimab). Data from 16 patients with advanced cancer treated with weekly infusions between 1 mg/kg and 6 mg/kg were presented at the ESMO Congress 2018 in Munich, Germany. The preAlready a subscriber Login You have…
